Literature DB >> 29924583

Arg-Phe-Phe d-Amino Acid Stereochemistry Scan in the Macrocyclic Agouti-Related Protein Antagonist Scaffold c[Pro-Arg-Phe-Phe-Xxx-Ala-Phe-DPro] Results in Unanticipated Melanocortin-1 Receptor Agonist Profiles.

Mark D Ericson1, Zoe M Koerperich1, Katie T Freeman1, Katlyn A Fleming1, Carrie Haskell-Luevano1.   

Abstract

The melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R), endogenous agonists derived from the proopiomelanocortin gene transcript, and naturally occurring antagonists agouti and agouti-related protein (AGRP) have been linked to biological pathways associated with energy homeostasis. The active tripeptide sequence of AGRP, Arg111-Phe112-Phe113, is located on a hypothesized β-hairpin loop. Herein, stereochemical modifications of the Arg-Phe-Phe sequence were examined in the octapeptide AGRP-derived macrocyclic scaffold c[Pro-Arg-Phe-Phe-Xxx-Ala-Phe-DPro], where Xxx was Asn or diaminopropionic acid (Dap). Macrocyclic peptides were synthesized with one, two, or three residues of the Arg-Phe-Phe sequence substituted with the corresponding d-isomer(s), generating a 14 compound library. While l-to-d inversions of the Arg-Phe-Phe sequence in a 20-residue AGRP-derived ligand previously resulted in agonist activity at the MC1R, MC3R, MC4R, and MC5R, only the MC1R was consistently stimulated by the macrocyclic ligands in the present study, with varying ligand potencies and efficacies observed at the MC1R. A general trend of increased MC4R antagonist potency was observed for Dap-containing compounds, while MC5R inverse agonist activity was observed for select ligands. It was observed that stereochemical modification of the Arg-Phe-Phe active tripeptide sequence was insufficient to convert melanocortin antagonist into agonists. Overall, these observations are important in the design of melanocortin ligands possessing potent and selective agonist and antagonist activities.

Entities:  

Keywords:  AGRP; d-amino acids; macrocycles; melanocortin receptors

Mesh:

Substances:

Year:  2018        PMID: 29924583      PMCID: PMC6339850          DOI: 10.1021/acschemneuro.8b00218

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  46 in total

1.  A Macrocyclic Agouti-Related Protein/[Nle4,DPhe7]α-Melanocyte Stimulating Hormone Chimeric Scaffold Produces Subnanomolar Melanocortin Receptor Ligands.

Authors:  Mark D Ericson; Katie T Freeman; Sathya M Schnell; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-01-17       Impact factor: 7.446

Review 2.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

3.  Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor.

Authors:  C Haskell-Luevano; E K Monck
Journal:  Regul Pept       Date:  2001-05-05

4.  Implication of the melanocortin-3 receptor in the regulation of food intake.

Authors:  Boman G Irani; Zhimin Xiang; Hossein N Yarandi; Jerry R Holder; Marcus C Moore; Rayna M Bauzo; Bettina Proneth; Amanda M Shaw; William J Millard; James B Chambers; Stephen C Benoit; Deborah J Clegg; Carrie Haskell-Luevano
Journal:  Eur J Pharmacol       Date:  2011-01-01       Impact factor: 4.432

5.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass.

Authors:  A S Chen; D J Marsh; M E Trumbauer; E G Frazier; X M Guan; H Yu; C I Rosenblum; A Vongs; Y Feng; L Cao; J M Metzger; A M Strack; R E Camacho; T N Mellin; C N Nunes; W Min; J Fisher; S Gopal-Truter; D E MacIntyre; H Y Chen; L H Van der Ploeg
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.

Authors:  Karine Clément; Heike Biebermann; I Sadaf Farooqi; Lex Van der Ploeg; Barbara Wolters; Christine Poitou; Lia Puder; Fred Fiedorek; Keith Gottesdiener; Gunnar Kleinau; Nicolas Heyder; Patrick Scheerer; Ulrike Blume-Peytavi; Irina Jahnke; Shubh Sharma; Jacek Mokrosinski; Susanna Wiegand; Anne Müller; Katja Weiß; Knut Mai; Joachim Spranger; Annette Grüters; Oliver Blankenstein; Heiko Krude; Peter Kühnen
Journal:  Nat Med       Date:  2018-05-07       Impact factor: 53.440

7.  Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice.

Authors:  J R Shutter; M Graham; A C Kinsey; S Scully; R Lüthy; K L Stark
Journal:  Genes Dev       Date:  1997-03-01       Impact factor: 11.361

8.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

9.  Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

Authors:  Peter Kühnen; Karine Clément; Susanna Wiegand; Oliver Blankenstein; Keith Gottesdiener; Lea L Martini; Knut Mai; Ulrike Blume-Peytavi; Annette Grüters; Heiko Krude
Journal:  N Engl J Med       Date:  2016-07-21       Impact factor: 91.245

10.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

View more
  1 in total

1.  Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AgRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists.

Authors:  Zoe M Koerperich; Mark D Ericson; Katie T Freeman; Robert C Speth; Irina D Pogozheva; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2020-01-06       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.